Please provide your email address to receive an email when new articles are posted on . 25% of patients experienced a gap of 60 days or more since they last filled their prescription. Patients with ...
The US Food and Drug Administration (FDA) has expanded the approval of Dupixent (dupilumab) to include adolescents aged 12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal ...
This new study explored how expression of SERPINB10 may be related to postoperative recurrence of and inflammation related to chronic rhinosinusitis with nasal polyps (CRSwNP). SERPINB10, a ...
The approval in adolescent patients was based on evidence from the phase 3 SINUS-24 and SINUS-52 trials. The Food and Drug Administration (FDA) has expanded the approval of Dupixent ® (dupilumab) to ...
GlaxoSmithKline ( ($GB:GSK) ) has shared an update. GSK has announced that the European Medicines Agency’s Committee for Medicinal Products for ...
The investigators of a new study evaluated if nasal cytology was a reliable method to identify type 2 inflammation in patients who have chronic rhinosinusitis with nasal polyps (CRSwNP), which could ...
A regulatory decision for expansion of the CRSwNP indication to adolescents is expected on September 15, 2024. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental ...
TARRYTOWN, N.Y. and PARIS, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved ...
Please provide your email address to receive an email when new articles are posted on . Outcomes improved with mepolizumab regardless of one or more past surgeries. For surgery risk and oral ...
Dupilumab significantly outperformed omalizumab in reducing the size of nasal polyps and improving sense of smell in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting ...
GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...
The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with nasal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback